Management of recurrent prostate cancer

**Location:** Room 14b (ICM, Level 1)

**Chairs:**
- A. Bjartell, Malmö (SE)
- A. Ponholzer, Vienna (AT)
- J. Rubio Briones, Valencia (ES)

**Aims and objectives of this presentation**
Managing PSA recurrence after radical treatment remains one of the more difficult challenges in modern urology. That implies early identification and correct prognostication of individual risk. This session will present the latest update on the topic.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*544 Long-term impact of adjuvant versus early salvage radiation therapy on clinical recurrence in pT3N0 prostate cancer patients treated with radical prostatectomy: Results of a multi-institutional analysis*

**By:** Fossati N.¹, Karnes J.², Morlacco A.³, Moschini M.¹, Boorjian S.², Seisen T.³, Bossi A.³, Cozzarini C.⁴, Fiorino C.⁴, Noris Chiorda B.⁴, Gandaglia G.⁴, Tosco L.⁴, De Ridder D.⁵, Joniau S.⁵, Goldner G.⁶, Shariat S.⁷, Hinkelbein W.⁷, Haustermans K.⁷, Tombal B.⁸, Montorsi F.¹, Van Poppel H.⁹, Wiegel T.¹¹, Briganti A.¹

**Institutes:** ¹IRCCS Ospedale San Raffaele, Dept. of Oncology/Unit of Urology; URI, Milan, Italy, ²Mayo Clinic, Dept. of Urology, Rochester, United States of America, ³Gustave Roussy Institute, Dept. of Radiation Oncology, Villejuif, France, ⁴IRCCS Ospedale San Raffaele, Dept. of Radiotherapy, Milan, Italy, ⁵University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ⁶Medical University of Vienna, Dept. of Radio Oncology, Vienna, Austria, ⁷Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁸Charité Universita¨tsmedizin, Campus Benjamin Franklin, Dept. of Radiation Oncology, Berlin, Germany, ⁹University Hospitals Leuven, Dept. of Radiotherapy, Leuven, Belgium, ¹⁰Universite´ Catholique De Louvain, Dept. of Urology, Brussels, Belgium, ¹¹University Hospital Ulm, Dept. of Radiation Oncology, Ulm, Germany

*545 Early salvage radiotherapy gives favorable results in unfavorable prostate cancer patient subgroups*

**By:** Wiegel T.¹, Bartkowiak D.¹, Bottke D.¹, Siegmann A.², Böhmer D.², Budach V.²

**Institutes:** ¹University Hospital Ulm, Dept. of Radiation Oncology, Ulm, Germany, ²University Hospital Berlin, Dept. of Radiation Oncology, Berlin, Germany

*546 Patterns of recurrence and long-term cancer-specific mortality of prostate cancer patients treated with salvage radical prostatectomy for radio-recurrent prostate cancer*

**By:** Gandaglia G.¹, Fossati N.², Suardi N.², Gallina A.², Colombo R.², Bertini R.², Dehò F.², Scattoni V.², Stabile A.², Cozzarini C.³, Rigatti P.⁴, Montorsi F.², Briganti A.²

**Institutes:** ¹Ircss Ospedale San Raffaele; Uri, Dept. of Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Oncology/Unit of Urology; URI, Milan, Italy, ³IRCCS Ospedale San Raffaele, Dept. of Radiotherapy, Milan, Italy, ⁴Advanced Urotechnology Center, Istituto Auxologico Italiano, Dept. of Urology, Milan, Italy

*547 Clinical utility of PET-PSMA in decision-making for prostate cancer patients: Preliminary analysis of 42 consecutive patients*

**By:** Albisinni S.¹, Artigas C.², Aoun F.¹, Biaou I.¹, Limani K.¹, Hawaux E.¹, Peltier A.¹, Flamen P.², Van
68Ga-PSMA has high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment.

By: Van Leeuwen P.¹, Emmett L.², Hruby G.², Kneebone A.³, Stricker P.¹

Institutes: St Vincent’s Prostate Cancer Centre, Dept. of Urology, Sydney, Australia, ²St Vincent’s Public Hospital, Dept. of Diagnostic Imaging, Sydney, Australia, ³Northern Sydney Cancer Centre, Royal North Shore Hospital, Dept. of Radiation Oncology, Sydney, Australia

Results of a prospective phase I/II randomized trial of peptide-specific vaccination in HLA-A*0201 positive prostate carcinoma patients with biochemical recurrence after radical prostatectomy.

By: Bedke J.¹, Gouttefangeas C.², Feyerabend S.¹, Hennenlotter J.¹, Avilés Escobar C.M.¹, Laske K.², Widenmeyer M.², Griesemann H.², Stevanovic S.², Rammensee H-G.², Stenzl A.¹

Institutes: University of Tübingen, Dept. of Urology, Tübingen, Germany, ²University of Tübingen, Dept. of Immunology, Tübingen, Germany

Oncologic outcomes and biochemical predictors following salvage lymph node dissection for prostate cancer.

By: Zattoni E.¹, Nehra A.¹, Lowe V.², Rangel L.¹, Mynderse L.¹, Kwon E.¹, Karnes J.¹

Institutes: Mayo Clinic, Dept. of Urology, Rochester, United States of America, ²Mayo Clinic, Dept. of Radiology, Rochester, United States of America

Feasibility of ¹¹¹In-PSMA-guided surgery for treatment of nodal prostate cancer relapse.

By: Schaal K.¹, Stoykow C.², Mix M.², Bartholomä M.², Drendel V.³, Mäcke H.², Gourni E.², Wetterauer U.¹, Schultze-Seemann W.¹, Meyer P.², Jilg C.A.¹

Institutes: University Medical Center Freiburg, Dept. of Urology, Freiburg, Germany, ²University Medical Center Freiburg, Dept. of Nuclear Medicine, Freiburg, Germany, ³University Medical Center Freiburg, Dept. of Pathology, Freiburg, Germany

Predicting the 5-year risk of biochemical relapse after post-prostatectomy radiotherapy in ≥pT2 patients with a comprehensive radiobiological model.

By: Fiorino C.¹, Broggi S.¹, Fossati N.², Cozzarini C.³, Goldner G.⁴, Wiegel T.⁵, Hinkelbein W.⁶, Karnes J.⁷, Haustermans K.⁸, Joniau S.⁹, De Ridder D.⁹, Shariat S.¹⁰, Montorsi F.¹, Van Poppel H.¹, Di Muzio N.², Calandrino R.¹, Briganti A.²

Institutes: IRCCS Ospedale San Raffaele, Dept. of Medical Physics, Milan, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Oncology and Urology, Milan, Italy, ³IRCCS Ospedale San Raffaele, Dept. of Radiotherapy, Milan, Italy, ⁴Medical University of Vienna, Dept. of Radiation Oncology, Vienna, Austria, ⁵University Hospital Ulm, Dept. of Radiation Oncology, Ulm, Germany, ⁶Charite Universita ßtsmedizin, Campus Benjamin Franklin, Dept. of Radiation Oncology, Berlin, Germany, ⁷Mayo Clinic, Dept. of Urology, Rochester, United States of America, ⁸University Hospitals Leuven, Dept. of Radiotherapy, Leuven, Belgium, ⁹University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ¹⁰Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Dept. of Urology, Vienna, Austria

Salvage tomotherapy choline PET/CT guided for prostate cancer lymph nodal recurrence.

By: Fodor A.¹, Genoveffa B.¹, Fiorino C.², Picchio M.², Busnardo E.³, Kirienko M.⁴, Incerti E.⁵, Cozzarini C.¹, Dell’Oca L.¹, Mangili P.², Pasetti M.¹, Calandrino R.², Gianolli L.³, Di Muzio N.G.¹

Institutes: ¹San Raffaele Scientific Institute, Dept. of Radiotherapy, Milan, Italy, ²San Raffaele Scientific Institute, Dept. of Medical Physics, Milan, Italy, ³San Raffaele Scientific Institute, Dept. of Nuclear Medicine, Milan, Italy, ⁴University Milano-Bicocca, Dept. of Nuclear Medicine, Milan, Italy

Does salvage lymphadenectomy for biochemical progression following radical prostatectomy and additional radiotherapy have an impact on overall survival? Initial results from a case-control study.

By: Jilg C.A.¹, Tennstedt P.², Heinzner H.², Wetterauer U.¹, Grosu A.³, Budaesu L.², Schultze-Seemann W.¹, Steuber T.²

Institutes: University Medical Center Freiburg, Dept. of Urology, Freiburg, Germany, ²Martini-Clinic,
**Poster Session 44**

University Hospital Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ³University Medical Center Freiburg, Dept. of Radiation Oncology, Freiburg, Germany

*555*

**Long-term oncological outcomes of salvage cryotherapy for radio-recurrent prostate cancer**

By: Siddiqui K.¹, Billia M.¹, Violette P.², Arifin A.¹, Tran K.¹, Chin J.¹

**Institutes:** University of Western Ontario, Dept. of Urology, London, Canada, ²Woodstock Hospital, Dept. of Urology, Woodstock, Canada

*556*

**A prospective phase II clinical trial of salvage whole gland high intensity focused ultrasound for radio-recurrent prostate: Intermediate term results**

By: Siddiqui K.¹, Billia M.¹, Violette P.², Chin J.²

**Institutes:** University of Western Ontario, Dept. of Urology, London, Canada, ²Woodstock Hospital, Dept. of Urology, London, Canada

15:17 - 15:24

Summary and context

J. Rubio Briones, Valencia (ES)